ASIA-PACIFIC ANTI FUNGAL MARKET FORECAST 2017-2025
KEY FINDINGS
Asia Pacific antifungal agents market is expected to grow at a CAGR of 10.33% in the forecasted period of 2017-2025. The market was calculated to be $1648 million in 2016 and is expected to hit $3959 million by 2025. Poor hygiene, developing new drug resistance are some of the factors helping the market to surge ahead.
MARKET INSIGHTS
The antifungal agent market segmentation by drug types is on the basis of Echinocandins market, Azoles market, Polyenes market, Allylamines and others. It is further segmented by therapeutic indications on the basis of Aspergillosis, Dermatophytosis and Candidiasis market. It is further divided by applications on the basis of topical antifungal agents and Oral drugs market. Initiatives taken by the government in healthcare policies and programs is the major factor responsible for the growth of the antifungal agent market in Asia pacific region. Alternate treatment options and regulatory conditions are the restraints faced by the anti-fungal market.
COMPETITIVE INSIGHTS
The major market players in the antifungal market are Abbott Laboratories, Arbor PharmaceuticalsINC, Baxter, Astellas Pharma Inc, Bayer Healthcare, Teva Pharmaceuticals, Gilead, GlaxoSmithKline, Johnson&Johnson, Kramer Laboratories, Merck Co, Novartis and Pfizer, Sanofi- Aventis, Vertex Pharmaceuticals.
Asia Pacific antifungal agents market is expected to grow at a CAGR of 10.33% in the forecasted period of 2017-2025. The market was calculated to be $1648 million in 2016 and is expected to hit $3959 million by 2025. Poor hygiene, developing new drug resistance are some of the factors helping the market to surge ahead.
MARKET INSIGHTS
The antifungal agent market segmentation by drug types is on the basis of Echinocandins market, Azoles market, Polyenes market, Allylamines and others. It is further segmented by therapeutic indications on the basis of Aspergillosis, Dermatophytosis and Candidiasis market. It is further divided by applications on the basis of topical antifungal agents and Oral drugs market. Initiatives taken by the government in healthcare policies and programs is the major factor responsible for the growth of the antifungal agent market in Asia pacific region. Alternate treatment options and regulatory conditions are the restraints faced by the anti-fungal market.
COMPETITIVE INSIGHTS
The major market players in the antifungal market are Abbott Laboratories, Arbor PharmaceuticalsINC, Baxter, Astellas Pharma Inc, Bayer Healthcare, Teva Pharmaceuticals, Gilead, GlaxoSmithKline, Johnson&Johnson, Kramer Laboratories, Merck Co, Novartis and Pfizer, Sanofi- Aventis, Vertex Pharmaceuticals.
1. RESEARCH SCOPE
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROCH
2.3. BOTTOM UP-APPROACH
2.4. DATA TRIANGULATION
2.5. ESTIMATION METHODOLOGY
3. EXECUTIVE SUMMARY
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
4. MARKET DYANAMICS
4.1. DRIVERS
4.1.1. POOR HYGIENE HABITS
4.1.2. DEVELOPMENT OF DRUG RESISTANCE
4.1.3. HEALTHCARE POLICIES AND PROGRAMS BY GOVERNMENT
4.2. RESTRAINTS
4.2.1. ALTERNATE TREATMENT OPTIONS
4.2.2. REGULATORY ATMOSPHERE
4.3. OPPORTUNITIES
4.3.1. HEALTHCARE AND RELATED INDUSTRIES ARE GROWING CONTINUOUSLY
4.3.2. INCREASING AWARENESS AND AVAILABILITY OF INFORMATION
4.4. CHALLENGES
4.4.1. SIDE EFFECTS AND RECURRING FUNGAL INFECTIONS
4.4.2. RESISTANCE TO DRUG
4.4.3. RAPIDLY CHANGING TECHNOLOGY
5. MARKET SEGMENTATION
5.1. BY DRUG TYPES
5.1.1. ECHINOCANDINS MARKET
5.1.2. AZOLES MARKET
5.1.3. POLYENES MARKET
5.1.4. ALLYLAMINES MARKET
5.1.5. OTHERS MARKET
5.2. BY THERAPEUTIC INDICATIONS
5.2.1. ASPERGILLOSIS MARKET
5.2.2. DERMATOPHYTOSIS MARKET
5.2.3. CANDIDIASIS MARKET
5.2.4. OTHERS MARKET
5.3. BY APPLICATIONS
5.3.1. TOPICAL ANTIFUNGAL AGENTS MARKET
5.3.2. ORAL DRUGS MARKET
6. KEY ANALYTICS
6.1. PORTER’S FIVE FORCE MODEL
6.1.1. THREAT OF NEW ENTRANTS
6.1.2. THREAT OF SUBSTITUTE PRODUCTS OR SERVICES
6.1.3. BARGAINING POWER OF BUYER
6.1.4. BARGAINING POWER OF SUPPLIER
6.1.5. INTENSITY OF COMPETITIVE RIVALRY
6.2. PESTEL ANALYSIS
6.3. KEY BUYING CRITERIA
6.4. VALUE CHAIN ANALYSIS
6.5. STRATEGIC RECOMMENDATION
6.6. STRATEGIC CONCLUSIONS
6.7. OPPORTUNITY MATRIX
6.8. VENDOR LANDSCAPE
7. GEOGRAPHICAL ANALYSIS
7.1. ASIA PACIFIC ANTI FUNGAL AGENTS MARKET
7.1.1. INDIA ANTI FUNGAL AGENTS MARKET
7.1.2. CHINA ANTI FUNGAL AGENTS MARKET
7.1.3. JAPAN ANTI FUNGAL AGENTS MARKET
7.1.4. ROAPAC ANTI FUNGAL AGENTS MARKET
8. COMPETITIVE LANDSCAPE
8.1. MARKET SHARE ANALYSIS
8.2. TOP WINNING STRATEGIES
9. COMPANY PROFILES
9.1. ABBOTT LABORATORIES.
9.1.1. OVERVIEW
9.1.2. PRODUCT PORTFOLIO
9.1.3. SCOT ANALYSIS
9.1.4. STRATEGIC INITIATIVES
9.2. ARBOR PHARMACEUTICALS, INC.
9.2.1. OVERVIEW
9.2.2. PRODUCT PORTFOLIO
9.2.3. SCOT ANALYSIS
9.2.4. STRATEGIC INITIATIVES
9.3. 3 BAXTER
9.3.1. OVERVIEW
9.3.2. PRODUCT PORTFOLIO
9.3.3. SCOT ANALYSIS
9.3.4. STRATEGIC INITIATIVES
9.4. ASTELLAS PHARMA INC.
9.4.1. OVERVIEW
9.4.2. PRODUCT PORTFOLIO
9.4.3. SCOT ANALYSIS
9.4.4. STRATEGIC INITIATIVES
9.5. BAYER HEALTHCARE
9.5.1. OVERVIEW
9.5.2. PRODUCT PORTFOLIO
9.5.3. SCOT ANALYSIS
9.5.4. STRATEGIC INITIATIVE
9.6. TEVA PHARMACEUTICALS
9.6.1. OVERVIEW
9.6.2. PRODUCT PORTFOLIO
TABLE LIST
TABLE 1 INDICATION AND DOSES OF ECHINOCANDIN
TABLE 2 ASIA-PACIFIC ECHINOCANDINS MARKET 2017-2025 ($ MILLION)
TABLE 3 DRUG USES OF TRIAZOLES
TABLE 4 ASIA-PACIFIC AZOLES MARKET 2017-2025 ($ MILLION)
TABLE 5 ASIA-PACIFIC POLYENES MARKET 2017-2025 ($ MILLION)
TABLE 6 PRICE OF ALLYLAMINE ANTIFUNGALS
TABLE 7 ASIA-PACIFIC ALLYLAMINES MARKET 2017-2025 ($ MILLION)
TABLE 8 ASIA-PACIFIC ASPERGILLOSIS MARKET 2017-2025 ($ MILLION)
TABLE 9 COMMON AFFECTED AREA - DERMATOPHYTES
TABLE 10 ASIA-PACIFIC DERMATOPHYTOSIS MARKET 2017-2025 ($ MILLION)
TABLE 11 SYMPTOMS IN THE AFFECTED AREA CAUSED BY CANDIDIASIS
TABLE 12 ASIA-PACIFIC CANDIDIASIS MARKET 2017-2025 ($ MILLION)
TABLE 13 ASIA-PACIFIC OTHERS MARKET 2017-2025 ($ MILLION)
TABLE 14 PROS AND CONS OF TOPICAL MEDICATIONS
TABLE 15 BRANDS OF ANTIFUNGAL POWDERS AND THEIR FUNCTIONALITY
TABLE 16 BRANDS OF ANTIFUNGAL OINTMENTS AND THEIR FUNCTIONALITY
TABLE 17 ANTIFUNGAL PASTES AND its EFFECT
TABLE 18 COMMONLY USED ANTIFUNGAL DRUGS DOSAGE AND IT’S EFFECTS
TABLE 19 ASIA PACIFIC ANTI FUNGAL AGENTS MARKET 2017-2025 ($ MILLION)
TABLE 20 INDIA’S HEALTHCARE SECTOR INVESTMENT
TABLE 21 COMPANIES IN CHINA PRODUCING ANTIFUNGAL DRUGS
TABLE 22 TOTAL BURDENS OF FUNGAL INFECTIONS IN JAPAN
FIGURES LIST
FIGURE 1 HEALTHCARE PROGRAMS INITIATED BY INDAINGOVENMENT
FIGURE 2 HEATHCARE INDUSTRIES IN THE WORLD IS RAPIDLY GROWING (%)
FIGURE 3 ASIA-PACIFIC ECHINOCANDINS MARKET 2017-2025 ($ MILLION)
FIGURE 4 ASIA-PACIFIC AZOLES MARKET 2017-2025 ($ MILLION)
FIGURE 5 ASIA-PACIFIC POLYENES MARKET 2017-2025 ($ MILLION)
FIGURE 6 ASIA-PACIFIC ALLYLAMINES MARKET 2017-2025 ($ MILLION)
FIGURE 7 ASIA-PACIFIC OTHERS MARKET 2017-2025 ($ MILLION)
FIGURE 8 ASIA-PACIFIC ASPERGILLOSIS MARKET 2017-2025 ($ MILLION)
FIGURE 9 ASIA-PACIFIC DERMATOPHYTOSIS MARKET 2017-2025 ($ MILLION)
FIGURE 10 ASIA-PACIFIC CANDIDIASIS MARKET 2017-2025 ($ MILLION)
FIGURE 11 ASIA-PACIFIC OTHERS MARKET 2017-2025 ($ MILLION)
FIGURE 12 TOPICAL ANTIFUNGAL AGENTS TYPES
FIGURE 13 ASIA-PACIFIC TOPICAL ANTIFUNGAL AGENTS MARKET 2017-2025 ($ MILLION)
FIGURE 14 ASIA-PACIFIC ORAL DRUGS MARKET 2017-2025 ($ MILLION)
FIGURE 15 PORTER’S FIVE FORCE MODEL IN ANTIFUNGAL AGENTS MARKET
FIGURE 16 PER CAPITA HEALTHCARE EXPENDITURE IN INDIA ($)
FIGURE 17 INDIA ANTI FUNGAL AGENTS MARKET 2017-2025 ($ MILLION)
FIGURE 18 CHINA ANTI FUNGAL AGENTS MARKET 2017-2025 ($ MILLION)
FIGURE 19 JAPAN ANTI FUNGAL AGENTS MARKET 2017-2025 ($ MILLION)
FIGURE 20 ROAPAC ANTI FUNGAL AGENTS MARKET 2017-2025 ($ MILLION)
1.1. STUDY GOALS
1.2. SCOPE OF THE MARKET STUDY
1.3. WHO WILL FIND THIS REPORT USEFUL?
1.4. STUDY AND FORECASTING YEARS
2. RESEARCH METHODOLOGY
2.1. SOURCES OF DATA
2.1.1. SECONDARY DATA
2.1.2. PRIMARY DATA
2.2. TOP DOWN APPROCH
2.3. BOTTOM UP-APPROACH
2.4. DATA TRIANGULATION
2.5. ESTIMATION METHODOLOGY
3. EXECUTIVE SUMMARY
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
4. MARKET DYANAMICS
4.1. DRIVERS
4.1.1. POOR HYGIENE HABITS
4.1.2. DEVELOPMENT OF DRUG RESISTANCE
4.1.3. HEALTHCARE POLICIES AND PROGRAMS BY GOVERNMENT
4.2. RESTRAINTS
4.2.1. ALTERNATE TREATMENT OPTIONS
4.2.2. REGULATORY ATMOSPHERE
4.3. OPPORTUNITIES
4.3.1. HEALTHCARE AND RELATED INDUSTRIES ARE GROWING CONTINUOUSLY
4.3.2. INCREASING AWARENESS AND AVAILABILITY OF INFORMATION
4.4. CHALLENGES
4.4.1. SIDE EFFECTS AND RECURRING FUNGAL INFECTIONS
4.4.2. RESISTANCE TO DRUG
4.4.3. RAPIDLY CHANGING TECHNOLOGY
5. MARKET SEGMENTATION
5.1. BY DRUG TYPES
5.1.1. ECHINOCANDINS MARKET
5.1.2. AZOLES MARKET
5.1.3. POLYENES MARKET
5.1.4. ALLYLAMINES MARKET
5.1.5. OTHERS MARKET
5.2. BY THERAPEUTIC INDICATIONS
5.2.1. ASPERGILLOSIS MARKET
5.2.2. DERMATOPHYTOSIS MARKET
5.2.3. CANDIDIASIS MARKET
5.2.4. OTHERS MARKET
5.3. BY APPLICATIONS
5.3.1. TOPICAL ANTIFUNGAL AGENTS MARKET
5.3.2. ORAL DRUGS MARKET
6. KEY ANALYTICS
6.1. PORTER’S FIVE FORCE MODEL
6.1.1. THREAT OF NEW ENTRANTS
6.1.2. THREAT OF SUBSTITUTE PRODUCTS OR SERVICES
6.1.3. BARGAINING POWER OF BUYER
6.1.4. BARGAINING POWER OF SUPPLIER
6.1.5. INTENSITY OF COMPETITIVE RIVALRY
6.2. PESTEL ANALYSIS
6.3. KEY BUYING CRITERIA
6.4. VALUE CHAIN ANALYSIS
6.5. STRATEGIC RECOMMENDATION
6.6. STRATEGIC CONCLUSIONS
6.7. OPPORTUNITY MATRIX
6.8. VENDOR LANDSCAPE
7. GEOGRAPHICAL ANALYSIS
7.1. ASIA PACIFIC ANTI FUNGAL AGENTS MARKET
7.1.1. INDIA ANTI FUNGAL AGENTS MARKET
7.1.2. CHINA ANTI FUNGAL AGENTS MARKET
7.1.3. JAPAN ANTI FUNGAL AGENTS MARKET
7.1.4. ROAPAC ANTI FUNGAL AGENTS MARKET
8. COMPETITIVE LANDSCAPE
8.1. MARKET SHARE ANALYSIS
8.2. TOP WINNING STRATEGIES
9. COMPANY PROFILES
9.1. ABBOTT LABORATORIES.
9.1.1. OVERVIEW
9.1.2. PRODUCT PORTFOLIO
9.1.3. SCOT ANALYSIS
9.1.4. STRATEGIC INITIATIVES
9.2. ARBOR PHARMACEUTICALS, INC.
9.2.1. OVERVIEW
9.2.2. PRODUCT PORTFOLIO
9.2.3. SCOT ANALYSIS
9.2.4. STRATEGIC INITIATIVES
9.3. 3 BAXTER
9.3.1. OVERVIEW
9.3.2. PRODUCT PORTFOLIO
9.3.3. SCOT ANALYSIS
9.3.4. STRATEGIC INITIATIVES
9.4. ASTELLAS PHARMA INC.
9.4.1. OVERVIEW
9.4.2. PRODUCT PORTFOLIO
9.4.3. SCOT ANALYSIS
9.4.4. STRATEGIC INITIATIVES
9.5. BAYER HEALTHCARE
9.5.1. OVERVIEW
9.5.2. PRODUCT PORTFOLIO
9.5.3. SCOT ANALYSIS
9.5.4. STRATEGIC INITIATIVE
9.6. TEVA PHARMACEUTICALS
9.6.1. OVERVIEW
9.6.2. PRODUCT PORTFOLIO
TABLE LIST
TABLE 1 INDICATION AND DOSES OF ECHINOCANDIN
TABLE 2 ASIA-PACIFIC ECHINOCANDINS MARKET 2017-2025 ($ MILLION)
TABLE 3 DRUG USES OF TRIAZOLES
TABLE 4 ASIA-PACIFIC AZOLES MARKET 2017-2025 ($ MILLION)
TABLE 5 ASIA-PACIFIC POLYENES MARKET 2017-2025 ($ MILLION)
TABLE 6 PRICE OF ALLYLAMINE ANTIFUNGALS
TABLE 7 ASIA-PACIFIC ALLYLAMINES MARKET 2017-2025 ($ MILLION)
TABLE 8 ASIA-PACIFIC ASPERGILLOSIS MARKET 2017-2025 ($ MILLION)
TABLE 9 COMMON AFFECTED AREA - DERMATOPHYTES
TABLE 10 ASIA-PACIFIC DERMATOPHYTOSIS MARKET 2017-2025 ($ MILLION)
TABLE 11 SYMPTOMS IN THE AFFECTED AREA CAUSED BY CANDIDIASIS
TABLE 12 ASIA-PACIFIC CANDIDIASIS MARKET 2017-2025 ($ MILLION)
TABLE 13 ASIA-PACIFIC OTHERS MARKET 2017-2025 ($ MILLION)
TABLE 14 PROS AND CONS OF TOPICAL MEDICATIONS
TABLE 15 BRANDS OF ANTIFUNGAL POWDERS AND THEIR FUNCTIONALITY
TABLE 16 BRANDS OF ANTIFUNGAL OINTMENTS AND THEIR FUNCTIONALITY
TABLE 17 ANTIFUNGAL PASTES AND its EFFECT
TABLE 18 COMMONLY USED ANTIFUNGAL DRUGS DOSAGE AND IT’S EFFECTS
TABLE 19 ASIA PACIFIC ANTI FUNGAL AGENTS MARKET 2017-2025 ($ MILLION)
TABLE 20 INDIA’S HEALTHCARE SECTOR INVESTMENT
TABLE 21 COMPANIES IN CHINA PRODUCING ANTIFUNGAL DRUGS
TABLE 22 TOTAL BURDENS OF FUNGAL INFECTIONS IN JAPAN
FIGURES LIST
FIGURE 1 HEALTHCARE PROGRAMS INITIATED BY INDAINGOVENMENT
FIGURE 2 HEATHCARE INDUSTRIES IN THE WORLD IS RAPIDLY GROWING (%)
FIGURE 3 ASIA-PACIFIC ECHINOCANDINS MARKET 2017-2025 ($ MILLION)
FIGURE 4 ASIA-PACIFIC AZOLES MARKET 2017-2025 ($ MILLION)
FIGURE 5 ASIA-PACIFIC POLYENES MARKET 2017-2025 ($ MILLION)
FIGURE 6 ASIA-PACIFIC ALLYLAMINES MARKET 2017-2025 ($ MILLION)
FIGURE 7 ASIA-PACIFIC OTHERS MARKET 2017-2025 ($ MILLION)
FIGURE 8 ASIA-PACIFIC ASPERGILLOSIS MARKET 2017-2025 ($ MILLION)
FIGURE 9 ASIA-PACIFIC DERMATOPHYTOSIS MARKET 2017-2025 ($ MILLION)
FIGURE 10 ASIA-PACIFIC CANDIDIASIS MARKET 2017-2025 ($ MILLION)
FIGURE 11 ASIA-PACIFIC OTHERS MARKET 2017-2025 ($ MILLION)
FIGURE 12 TOPICAL ANTIFUNGAL AGENTS TYPES
FIGURE 13 ASIA-PACIFIC TOPICAL ANTIFUNGAL AGENTS MARKET 2017-2025 ($ MILLION)
FIGURE 14 ASIA-PACIFIC ORAL DRUGS MARKET 2017-2025 ($ MILLION)
FIGURE 15 PORTER’S FIVE FORCE MODEL IN ANTIFUNGAL AGENTS MARKET
FIGURE 16 PER CAPITA HEALTHCARE EXPENDITURE IN INDIA ($)
FIGURE 17 INDIA ANTI FUNGAL AGENTS MARKET 2017-2025 ($ MILLION)
FIGURE 18 CHINA ANTI FUNGAL AGENTS MARKET 2017-2025 ($ MILLION)
FIGURE 19 JAPAN ANTI FUNGAL AGENTS MARKET 2017-2025 ($ MILLION)
FIGURE 20 ROAPAC ANTI FUNGAL AGENTS MARKET 2017-2025 ($ MILLION)
